[Pefloxacin: evaluation and clinical prospects].
Following a summary of the main bacteriological and pharmacokinetic properties of this new quinolone derivative, the author reviews the results obtained with pefloxacine in the treatment of urinary tract infection, gonococcal urethritis, and bronchopulmonary, surgical, gynaecological, bone, soft tissue, neuromeningeal and ENT infections.
Modaï
J
J
D001424:Bacterial Infections / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D009643:Norfloxacin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010019:Osteomyelitis / Q000188:drug therapy; D015366:Pefloxacin; D014526:Urethritis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D015366:Pefloxacin; D009643:Norfloxacin
Péfloxacine: bilan et perspectives cliniques.